Ładuje się......
Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer
BACKGROUND: Nivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers. This study reviewed the HPD in patients with AGC treated with nivolumab or irinotec...
Zapisane w:
| Wydane w: | ESMO Open |
|---|---|
| Główni autorzy: | , , , , , , , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
BMJ Publishing Group
2019
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6555603/ https://ncbi.nlm.nih.gov/pubmed/31231567 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000488 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|